Pfizer (PFE) Competitors

Amgen (NASDAQ:AMGN) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Is AMGN or PFE a better dividend stock?

Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.4%. Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 7.2%. Amgen pays out 77.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer pays out 91.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen has raised its dividend for 14 consecutive years and Pfizer has raised its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Which has stronger valuation & earnings, AMGN or PFE?

Pfizer has higher revenue and earnings than Amgen. Pfizer is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$33.42B	4.45	$4.09B	$12.23	22.60
Pfizer	$63.63B	2.14	$8.03B	$1.88	12.72

Do analysts rate AMGN or PFE?

Amgen currently has a consensus price target of $304.43, indicating a potential upside of 10.14%. Pfizer has a consensus price target of $28.12, indicating a potential upside of 17.60%. Given Pfizer's stronger consensus rating and higher probable upside, analysts plainly believe Pfizer is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	2 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.32
Pfizer	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.39

Do institutionals & insiders have more ownership in AMGN or PFE?

76.5% of Amgen shares are owned by institutional investors. Comparatively, 68.4% of Pfizer shares are owned by institutional investors. 0.8% of Amgen shares are owned by insiders. Comparatively, 0.1% of Pfizer shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Is AMGN or PFE more profitable?

Amgen has a net margin of 18.96% compared to Pfizer's net margin of 16.84%. Amgen's return on equity of 174.71% beat Pfizer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	18.96%	174.71%	13.12%
Pfizer	16.84%	21.42%	9.12%

Which has more risk & volatility, AMGN or PFE?

Amgen has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500.

Does the media favor AMGN or PFE?

In the previous week, Pfizer had 26 more articles in the media than Amgen. MarketBeat recorded 77 mentions for Pfizer and 51 mentions for Amgen. Amgen's average media sentiment score of 1.32 beat Pfizer's score of 1.26 indicating that Amgen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	42 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Pfizer	62 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Amgen beats Pfizer on 11 of the 20 factors compared between the two stocks.